Revenue FY2025
$110.0M
Net Income
$(153.0M)
EPS (Basic)
$-3.19
Net Margin
-139.8%
ROE
145.5%
Total Equity
$(105.0M)
Shares Out
49M
UroGen Pharma Ltd. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2015–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 3 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
OrbiMed Advisors
OrbiMed Advisors
$24.9M
0.1%
(22.8%)
ARK Investment Management
ARK Investment Management
$3.7M
0.0%
(12.1%)
Polen Capital Management
Polen
$1.1M
0.0%
NEW
Insider Transactions
Reading stored insider transactions…